BNP Paribas Financial Markets grew its stake in shares of LivaNova PLC (NASDAQ:LIVN - Free Report) by 22.8% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 34,185 shares of the company's stock after acquiring an additional 6,340 shares during the quarter. BNP Paribas Financial Markets owned about 0.06% of LivaNova worth $1,583,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Russell Investments Group Ltd. increased its position in LivaNova by 17.1% during the 4th quarter. Russell Investments Group Ltd. now owns 1,502 shares of the company's stock worth $70,000 after purchasing an additional 219 shares in the last quarter. Sterling Capital Management LLC increased its position in LivaNova by 800.6% during the 4th quarter. Sterling Capital Management LLC now owns 1,621 shares of the company's stock worth $75,000 after purchasing an additional 1,441 shares in the last quarter. Vestcor Inc acquired a new stake in LivaNova during the 4th quarter worth approximately $204,000. Optimize Financial Inc acquired a new stake in LivaNova during the 4th quarter worth approximately $208,000. Finally, Inceptionr LLC acquired a new stake in LivaNova during the 4th quarter worth approximately $217,000. Institutional investors and hedge funds own 97.64% of the company's stock.
Analysts Set New Price Targets
LIVN has been the subject of several recent research reports. Robert W. Baird increased their price objective on shares of LivaNova from $55.00 to $61.00 and gave the company an "outperform" rating in a research report on Thursday, May 8th. Barclays lowered their price objective on shares of LivaNova from $56.00 to $55.00 and set an "equal weight" rating for the company in a research report on Thursday, May 8th. Needham & Company LLC reaffirmed a "buy" rating and issued a $64.00 price objective on shares of LivaNova in a research report on Tuesday, May 13th. The Goldman Sachs Group lowered their price objective on shares of LivaNova from $64.00 to $55.00 and set a "buy" rating for the company in a research report on Monday, March 3rd. Finally, StockNews.com downgraded shares of LivaNova from a "strong-buy" rating to a "buy" rating in a research report on Thursday, May 8th. Two research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $59.17.
Check Out Our Latest Stock Report on LivaNova
LivaNova Trading Up 1.3%
Shares of LIVN opened at $44.40 on Monday. The business's 50-day moving average price is $38.39 and its 200 day moving average price is $44.81. The stock has a market capitalization of $2.42 billion, a P/E ratio of 105.71 and a beta of 0.84. LivaNova PLC has a 1-year low of $32.48 and a 1-year high of $62.04. The company has a current ratio of 3.37, a quick ratio of 2.87 and a debt-to-equity ratio of 0.46.
About LivaNova
(
Free Report)
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.
Read More
Want to see what other hedge funds are holding LIVN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for LivaNova PLC (NASDAQ:LIVN - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider LivaNova, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and LivaNova wasn't on the list.
While LivaNova currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
